Latest news:

BioStock article: Follicum’s CEO comments on the study approval and Vinnova grant

BioStock published an article on 4 February 2020 about Follicum, which can be read in full below. FOL-005, Follicum’s hair growth candidate, has received approval from German authorities to initiate a phase IIa study. Patient recruitment will commence shortly, and initial results are expected before the end of the year. The company’s aim is to then […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Follicum's presentation at LSX World Congress 2020

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




08 Jun 20
BIO International Convention

Follicum will attend the BIO International Convention in San Diego, USA, on 8-11 June 2020 The confe...